Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Infectious Disease · Hansen's Disease

The Path to Cure: Understanding Your Medications

At a Glance

Hansen's disease (leprosy) is fully curable with Multidrug Therapy (MDT), a 6- to 12-month course of antibiotics. Completing the full treatment regimen, which typically includes rifampin, dapsone, and clofazimine, is essential to eradicate the bacteria and protect your long-term nerve health.

The standard treatment for Hansen’s disease is highly effective and leads to a full cure [1]. Because the bacteria that cause the disease grow very slowly, your treatment will involve a combination of several antibiotics taken over many months [2]. This approach, called Multidrug Therapy (MDT), is designed to kill the bacteria and prevent them from becoming resistant to the medicine [3][4].

Global vs. US Treatment Approaches

Depending on where you receive care, your medication schedule may look slightly different, but the goal remains the same.

  • The WHO Standard (Global): The World Health Organization (WHO) provides “blister packs” containing three main drugs: Rifampin, Dapsone, and Clofazimine [5].
    • PB (Paucibacillary): 6 months of Rifampin and Dapsone [6].
    • MB (Multibacillary): 12 months of Rifampin, Dapsone, and Clofazimine [5][7].
  • The NHDP Standard (United States): The National Hansen’s Disease Program (NHDP) often recommends taking the medications daily rather than monthly for more consistent blood levels [8][9]. They also sometimes use a monthly regimen known as RMM (Rifampin, Moxifloxacin, and Minocycline) for patients who cannot tolerate standard drugs [8][10].

The Practical Routine of Taking MDT

Taking heavy antibiotics for 6 to 12 months requires consistency.

  • Daily Routine: You will likely take your medications once a day. Taking them with food can help minimize nausea, a common initial side effect [8].
  • Other Medications: Always ask your doctor or pharmacist before adding new over-the-counter pain medications, antacids, or vitamins, as some can interfere with how your body absorbs the antibiotics [11].

Understanding Your Medications

Each drug in your regimen plays a specific role, but like all strong medications, they require careful monitoring.

Dapsone: Safety First

Dapsone is a cornerstone of treatment, but it requires two important safety checks before you take your first dose:

  1. G6PD Screening: Your doctor must check for a genetic trait called G6PD deficiency [12]. If you have this deficiency, dapsone can cause your red blood cells to break down (hemolytic anemia) [13].
  2. HLA-B*13:01 Testing: This is a genetic marker that increases the risk of Dapsone Hypersensitivity Syndrome (DHS), a severe reaction involving fever, rash, and liver issues [14][15]. This screening is especially recommended for patients of Asian or Indian descent [16][17].

Clofazimine: The “Bronzing” Effect

Clofazimine is a powerful antibiotic that also helps reduce inflammation in the nerves [18]. Its most notable side effect is skin discoloration [19].

  • What it looks like: Your skin may develop a reddish-brown or “bronzed” tint, especially in areas exposed to the sun or where you have skin lesions [18][20].
  • Is it permanent? No. This discoloration is reversible, though it may take several months to fade after you finish your treatment [19][20]. Please be reassured: this bronzing is strictly cosmetic and painless; it does not hurt, weaken, or damage the skin [18].

Rifampin: The Powerhouse

Rifampin is the most potent killer of the bacteria [11]. One important thing to note is that it can turn your urine, sweat, or tears an orange or reddish color. This is harmless and expected [11].

Monitoring for Success

While on treatment, you are a partner in your own care. You should contact your doctor immediately if you experience [15][21]:

  • A new, widespread skin rash or high fever.
  • Yellowing of the eyes or skin (jaundice).
  • Severe abdominal pain or persistent diarrhea.
  • Unusual fatigue or shortness of breath (signs of anemia).

By completing your full course of MDT—even if you feel completely better after just a few weeks—you ensure the bacteria are totally eradicated and protect your long-term nerve health [2][22].

Common questions in this guide

What is Multidrug Therapy (MDT) for leprosy?
Multidrug Therapy (MDT) is the standard treatment for Hansen's disease. It involves taking a combination of antibiotics, typically rifampin, dapsone, and clofazimine, for 6 to 12 months to completely cure the infection and prevent drug resistance.
Why do I need a genetic test before taking dapsone?
Your doctor will check for a genetic trait called G6PD deficiency and a marker called HLA-B*13:01. These tests are critical because taking dapsone with these genetic factors can cause severe reactions, such as the breakdown of red blood cells or dangerous liver issues.
Will my skin change color during Hansen's disease treatment?
If your treatment includes the antibiotic clofazimine, your skin may develop a reddish-brown or bronzed tint. This discoloration is completely harmless, painless, and purely cosmetic. It will gradually fade over several months after you finish your medication.
Why is my urine orange after starting leprosy medication?
The antibiotic rifampin is known to turn body fluids like urine, sweat, and tears an orange or reddish color. This is a normal, harmless, and expected side effect of the medication that does not require stopping treatment.
What side effects require immediate medical attention while on MDT?
You should contact your doctor immediately if you develop a widespread skin rash, high fever, yellowing of the eyes or skin, severe abdominal pain, or unusual shortness of breath. These could be signs of a serious drug reaction that requires medical evaluation.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Will I be following the WHO monthly blister pack regimen or the US National Hansen's Disease Program (NHDP) daily medication protocol?
  2. 2.Have you performed a G6PD deficiency test and an HLA-B*13:01 genetic screening before I start dapsone?
  3. 3.If I develop a skin rash or a high fever in the first few weeks of treatment, what is the best way to contact your office immediately?
  4. 4.Can we discuss an alternative regimen (like RMM) if I find the side effects of clofazimine or dapsone too difficult to manage?
  5. 5.How frequently will we be monitoring my blood counts and liver function during my 6-month or 12-month course?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Uncommon Presentation of Lepromatous Leprosy in a Nonendemic Setting: A Case Report.

    Osman ME, Alharby TN, Alhabeeb Y, et al.

    Case reports in medicine 2025; (2025()):8232445 doi:10.1155/carm/8232445.

    PMID: 40979449
  2. 2

    Leprosy.

    Grijsen ML, Nguyen TH, Pinheiro RO, et al.

    Nature reviews. Disease primers 2024; (10(1)):90 doi:10.1038/s41572-024-00575-1.

    PMID: 39609422
  3. 3

    World Health Organization (WHO) antibiotic regimen against other regimens for the treatment of leprosy: a systematic review and meta-analysis.

    Lazo-Porras M, Prutsky GJ, Barrionuevo P, et al.

    BMC infectious diseases 2020; (20(1)):62 doi:10.1186/s12879-019-4665-0.

    PMID: 31959113
  4. 4

    Clinicobacteriological evaluation of leprosy patients with 1-5 skin lesions.

    Ansari AS, Saxena K, Singh KK, et al.

    International journal of mycobacteriology 2020; (9(2)):209-211 doi:10.4103/ijmy.ijmy_7_20.

    PMID: 32474546
  5. 5

    Assessment of Clinical, Histopathological, and Bacteriological Findings in Treated Leprosy Patients with Persistent Skin Lesions: A Retrospective Cohort Study.

    Patial M, Hanumanthu V, Chhabra S, et al.

    The American journal of tropical medicine and hygiene 2023; (109(6)):1260-1265 doi:10.4269/ajtmh.23-0084.

    PMID: 37931307
  6. 6

    Clinical and Histopathological Response to Multidrug Therapy in Paucibacillary Leprosy at the end of 6 Months: A Prospective Observational Study from Eastern India.

    Podder I, Saha A, Bandyopadhyay D

    Indian journal of dermatology 2018; (63(1)):47-52 doi:10.4103/ijd.IJD_80_17.

    PMID: 29527025
  7. 7

    [Late diagnosis nodular lepromatous leprosy from the Peruvian Amazon, with development of a type 2 reaction].

    Villegas-Chiroque M, Maldonado-Gómez W, Espino-Saavedra W, Ventura-Flores R

    Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia 2021; (38(5)):707-712 doi:10.4067/s0716-10182021000500707.

    PMID: 35506839
  8. 8

    Novel approaches in the treatment of Hansen's disease (Leprosy): a case series of multidrug therapy of monthly rifampin, moxifloxacin, and minocycline (RMM) in the United States.

    Franco-Paredes C, Garcia-Creighton E, Henao-Martínez A, et al.

    Therapeutic advances in infectious disease 2022; (9()):20499361221135885 doi:10.1177/20499361221135885.

    PMID: 36387060
  9. 9

    Hansen's disease patient in Ohio successfully treated with a monthly rifampin, minocycline, and moxifloxacin regimen: a case report.

    Sankovic DE, Hubal AL, Alhajj MA, et al.

    ASM case reports 2025; (1(5)) doi:10.1128/asmcr.00080-24.

    PMID: 41244968
  10. 10

    An alternative multidrug regimen for multibacillary Hansen's disease: a case report.

    Akhverdyan N, Cantor Z, Hawkins K

    Journal of medical case reports 2024; (18(1)):612 doi:10.1186/s13256-024-04971-9.

    PMID: 39732728
  11. 11

    [Hansen disease, an emergent condition in Chile].

    San-Martín Á, Carrasco C, Fica A, et al.

    Revista chilena de infectologia : organo oficial de la Sociedad Chilena de Infectologia 2018; (35(6)):722-728 doi:10.4067/S0716-10182018000600722.

    PMID: 31095196
  12. 12

    Challenges associated with dapsone for leprosy treatment in Indonesia - urgent need for access to alternative antimicrobial drugs.

    Krismawati H, Harianja M, Oktavian A, et al.

    The Lancet regional health. Southeast Asia 2025; (34()):100555 doi:10.1016/j.lansea.2025.100555.

    PMID: 40084155
  13. 13

    A retrospective cohort study of monthly rifampicin, ofloxacin and minocycline in the management of leprosy at the Hospital for Tropical Diseases, London, United Kingdom.

    Sivakumaran P, Barros B, Antonio Dias VL, et al.

    PLoS neglected tropical diseases 2024; (18(12)):e0012699 doi:10.1371/journal.pntd.0012699.

    PMID: 39652597
  14. 14

    The Dapsone Conundrum: Understanding Implications of Adverse Reactions to Dapsone Including Dapsone Hypersensitivity Syndrome in Leprosy Patients Treated With Multidrug Therapy.

    Dev A, Narang T, Thakur V, Dogra S

    International journal of dermatology 2025; (64(10)):1862-1869 doi:10.1111/ijd.17906.

    PMID: 40514800
  15. 15

    Dapsone Hypersensitivity Syndrome With Leukemoid Reaction and Severe Thrombocytosis.

    Pahadiya HR, Lakhotia M

    Cureus 2021; (13(3)):e14026 doi:10.7759/cureus.14026.

    PMID: 33889465
  16. 16

    The Function of HLA-B*13:01 Involved in the Pathomechanism of Dapsone-Induced Severe Cutaneous Adverse Reactions.

    Chen WT, Wang CW, Lu CW, et al.

    The Journal of investigative dermatology 2018; (138(7)):1546-1554 doi:10.1016/j.jid.2018.02.004.

    PMID: 29458119
  17. 17

    The HLA-B*13:01 and the dapsone hypersensitivity syndrome in Korean and Asian populations: genotype- and meta-analyses.

    Park HJ, Park JW, Kim SH, et al.

    Expert opinion on drug safety 2020; (19(10)):1349-1356 doi:10.1080/14740338.2020.1796965.

    PMID: 32700588
  18. 18

    Clofazimine-induced cutaneous hyperpigmentation as a source of stigma in the treatment of leprosy: A cross-sectional study.

    Nogueira AS, Garcia MAC, Silva MBD, et al.

    Tropical medicine & international health : TM & IH 2024; (29(4)):327-333 doi:10.1111/tmi.13977.

    PMID: 38348585
  19. 19

    Impact of Clofazimine Dosing on Treatment Shortening of the First-Line Regimen in a Mouse Model of Tuberculosis.

    Ammerman NC, Swanson RV, Bautista EM, et al.

    Antimicrobial agents and chemotherapy 2018; (62(7)) doi:10.1128/AAC.00636-18.

    PMID: 29735562
  20. 20

    Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China.

    Tang S, Yao L, Hao X, et al.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2015; (60(9)):1361-7 doi:10.1093/cid/civ027.

    PMID: 25605283
  21. 21

    Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil.

    Dalcolmo M, Gayoso R, Sotgiu G, et al.

    The European respiratory journal 2017; (49(3)) doi:10.1183/13993003.02445-2016.

    PMID: 28331044
  22. 22

    Leprosy review.

    Makhakhe L

    South African family practice : official journal of the South African Academy of Family Practice/Primary Care 2021; (63(1)):e1-e6 doi:10.4102/safp.v63i1.5311.

    PMID: 34797098

This page provides educational information about Hansen's disease medications. Always consult your infectious disease specialist or pharmacist regarding your specific Multidrug Therapy (MDT) regimen, drug interactions, and side effects.

Get notified when new evidence is published on Leprosy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.